View all newsletters
Sign up to our newsletters

Support 110 years of independent journalism.

  1. Science & Tech
  2. Coronavirus
30 April 2020updated 06 Oct 2020 9:45am

Remdesivir trial shows “clear cut“ evidence the drug can aid Covid-19 recovery

By Samuel Horti

A clinical trial has shown “clear-cut” evidence that the antiviral drug remdesivir can help patients recover quicker from Covid-19, the US’s top infectious disease expert has said.

The randomised controlled trial of more than 1,000 patients was shown to cut the number of days infected patients took to leave hospital by nearly a third. Those taking the drug recovered after an average of 11 days, compared with 15 for those given a placebo.

Dr Anthony Fauci, one of the leading officials in the US’s coronavirus taskforce, said the trial was “a very important proof of concept”, and that “it has proven… that a drug can block this virus”.

Previously, smaller trials of remdesivir had suggested the drug, initally developed to treat Ebola, did not have a significant impact on coronavirus.

 

Content from our partners
What is the UK’s vision for its tech sector?
Inside the UK's enduring love for chocolate

Select and enter your email address Your weekly guide to the best writing on ideas, politics, books and culture every Saturday. The best way to sign up for The Saturday Read is via saturdayread.substack.com The New Statesman's quick and essential guide to the news and politics of the day. The best way to sign up for Morning Call is via morningcall.substack.com Our Thursday ideas newsletter, delving into philosophy, criticism, and intellectual history. The best way to sign up for The Salvo is via thesalvo.substack.com Stay up to date with NS events, subscription offers & updates. Weekly analysis of the shift to a new economy from the New Statesman's Spotlight on Policy team. The best way to sign up for The Green Transition is via spotlightonpolicy.substack.com
  • Administration / Office
  • Arts and Culture
  • Board Member
  • Business / Corporate Services
  • Client / Customer Services
  • Communications
  • Construction, Works, Engineering
  • Education, Curriculum and Teaching
  • Environment, Conservation and NRM
  • Facility / Grounds Management and Maintenance
  • Finance Management
  • Health - Medical and Nursing Management
  • HR, Training and Organisational Development
  • Information and Communications Technology
  • Information Services, Statistics, Records, Archives
  • Infrastructure Management - Transport, Utilities
  • Legal Officers and Practitioners
  • Librarians and Library Management
  • Management
  • Marketing
  • OH&S, Risk Management
  • Operations Management
  • Planning, Policy, Strategy
  • Printing, Design, Publishing, Web
  • Projects, Programs and Advisors
  • Property, Assets and Fleet Management
  • Public Relations and Media
  • Purchasing and Procurement
  • Quality Management
  • Science and Technical Research and Development
  • Security and Law Enforcement
  • Service Delivery
  • Sport and Recreation
  • Travel, Accommodation, Tourism
  • Wellbeing, Community / Social Services
Visit our privacy Policy for more information about our services, how Progressive Media Investments may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications.
THANK YOU